scholarly journals Vitamin D in pediatric patients with obesity and arterial hypertension

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Živa Radulović ◽  
Zarja Polak Zupan ◽  
Aljoša Tomazini ◽  
Nataša Marčun Varda
Keyword(s):  
Blood Pressure ◽  
Vitamin D ◽  
Pediatric Patients ◽  
Normal Weight ◽  
Apolipoprotein A1 ◽  
Normal Blood ◽  
Control Group ◽  
Overweight Children ◽  
Normal Blood Pressure ◽  
Vitamin D Levels

AbstractThe purpose of this study was to find potential differences in vitamin D levels between different groups: overweight children with hypertension, normal-weight children with hypertension, overweight children with normal blood pressure and normal-weight children without hypertension, representing the control group. We also wanted to determine whether there are correlations between vitamin D levels and other clinical laboratory parameters, to evaluate the potential need for substitution. We measured vitamin D, homocysteine, total cholesterol, HDL, LDL, triglycerides, uric acid, glucose, apolipoprotein A1, apolipoprotein B, alkaline phosphatase, calcium, phosphate and magnesium serum levels in all groups. We also took anthropometric measurements (body weight, height, body mass index (BMI)) and observed patients’ blood pressure. The results were analyzed with SPSS statistic tool with basic statistical methods. The study included 175 children between 5 and 18 years of age. Fiftyseven were healthy (group A—control group), 41 normal-weight with hypertension (group B), 44 overweight with hypertension (group C) and 33 overweight with normal blood pressure (group D). The results showed statistically significant differences in values of vitamin D between all groups—A and B (p = 0.003), A and C (p < 0.001), A and D (p < 0.001), B and D (p = 0.043), B and C (0.030), except for groups C and D (p = 0.830). There were statistically significant correlations between vitamin D and BMI (r = − 0.196, p = 0.010), systolic pressure (r = − 0.190, p = 0.002), diastolic pressure (r = − 0.149, p = 0.050), homocysteine (r = − 0.208, p = 0.007), triglycerides (r = − 0.196, p = 0.011) and apolipoprotein A1 (r = 0.222, p = 0.007), confirmed in multivariate model. For the blood pressure, the higher the systolic blood pressure, the lower the average vitamin D was. The pilot study shows significant differences in serum vitamin D levels between all groups of children, apart from groups C and D. These results, combined with statistically significant correlations between vitamin D and systolic and diastolic blood pressure suggest the need for monitoring and potential substitution of vitamin D in in pediatric patients with hypertension.

scholarly journals Vitamin D In Pediatric Patients With Obesity And Arterial Hypertension

2021 ◽  
Author(s):  
Živa Radulović ◽  
Zarja Polak Zupan ◽  
Aljoša Tomazini ◽  
Nataša Marčun Varda
Keyword(s):  
Blood Pressure ◽  
Vitamin D ◽  
Pediatric Patients ◽  
Pearson Correlation ◽  
Serum Vitamin ◽  
Normal Weight ◽  
Apolipoprotein A1 ◽  
Control Group ◽  
Overweight Children ◽  
Vitamin D Levels

Abstract Aim The purpose of this study was finding potential discrepancies in vitamin D levels between different groups: overweight children with hypertension, normal-weight children with hypertension, overweight children and normal-weight children without hypertension –control group. We also wanted to determine whether there are correlations between vitamin D levels and other clinical laboratory parameters, to evaluate the need for substitution. Methods We measured vitamin D, homocysteine, total cholesterol, HDL, LDL, triglycerides, uric acid, glucose, apolipoprotein A1, apolipoprotein B, alkaline phosphatase, calcium, phosphate and magnesium serum levels in all groups. We also took anthropometric measurements (body weight, height, BMI) and observed patients’ blood pressure. The results were analyzed with SPSS statistic tool with the use of independent t-test, Pearson correlation test and multi-variate analysis of variance (MANOVA). Results The study included 175 children between 5 and 18 years of age. 57 were healthy (group A – control group), 41 normal-weight with hypertension (group B), 44 overweight with hypertension (group C) and 33 overweight (group D). The results showed statistically significant distinction in values of vitamin D between all groups -– A and B (p = 0.003), A and C (p = 0.000), A and D (p = 0.000), B and D (p = 0.043), B and C (0.030), except for groups C and D (p = 0.830). There were statistically significant correlations between vitamin D and BMI (r=-0.196, p = 0.010), systolic pressure (r=-0.190, p = 0.002), diastolic pressure (r=-0.149, p = 0.050), homocysteine (r=-0.208, p = 0.007), triglycerides (r=-0.196, p = 0.011) and apolipoprotein A1 (r = 0.222, p = 0.007) among all groups. Conclusion The pilot study shows significant differences in serum vitamin D levels between all groups of children, apart from groups C and D. these results, combined with statistically significant correlations between vitamin D and systolic and diastolic blood pressure suggest the need for monitoring and potential substitution of vitamin D in in pediatric patients with hypertension and/or overweight children.

Role of bradykinin B1 and B2 receptors in normal blood pressure regulation

2006 ◽  
Vol 291 (2) ◽  
pp. E268-E274 ◽  
Author(s):  
Arvi Duka ◽  
Irena Duka ◽  
Guohong Gao ◽  
Sherene Shenouda ◽  
Irene Gavras ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Receptor Gene ◽  
Normal Blood ◽  
Control Group ◽  
Normal Blood Pressure ◽  
Concurrent Administration ◽  
Vasoactive Factors ◽  
Hoe 140 ◽  
The Impact

With inhibition or absence of the bradykinin B2 receptor (B2R), B1R is upregulated and assumes some of the hemodynamic properties of B2R, indicating that both participate in the maintenance of normal vasoregulation or to development of hypertension. Herein we further evaluate the role of bradykinin in normal blood pressure (BP) regulation and its relationship with other vasoactive factors by selectively blocking its receptors. Six groups of Wistar rats were treated for 3 wk: one control group with vehicle alone, one with concurrent administration of B1R antagonist R-954 (70 μg·kg−1·day−1) and B2R antagonist HOE-140 (500 μg·kg−1·day−1), one with R-954 alone, one with HOE 140 alone, one with concurrent administration of both R-954 and HOE-140 plus the angiotensin antagonist losartan (5 mg·kg−1·day−1), and one with only losartan. BP was measured continuously by radiotelemetry. Only combined administration of B1R and B2R antagonists produced a significant BP increase from a baseline of 107–119 mmHg at end point, which could be partly prevented by losartan and was not associated with change in catecholamines, suggesting no involvement of the sympathoadrenal system. The impact of blockade of bradykinin on other vasoregulating systems was assessed by evaluating gene expression of different vasoactive factors. There was upregulation of the eNOS, AT1 receptor, PGE2 receptor, and tissue kallikrein genes in cardiac and renal tissues, more pronounced when both bradykinin receptors were blocked; significant downregulation of AT2 receptor gene in renal tissues only; and no consistent changes in B1R and B2R genes in either tissue. The results indicate that both B1R and B2R contribute to the maintenance of normal BP, but one can compensate for inhibition of the other, and the chronic inhibition of both leads to significant upregulation in the genes of related vasoactive systems.

scholarly journals Transcutaneous electrical acupoint stimulation for high-normal blood pressure: study protocol for a randomized controlled pilot trial

2020 ◽  
Author(s):  
Yu Wang ◽  
Guang-Xia Shi ◽  
Zhong-Xue Tian ◽  
Jun-Hong Liu ◽  
You-Sheng Qi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Lifestyle Modification ◽  
Intervention Group ◽  
Normal Blood ◽  
Control Group ◽  
Efficacy And Safety ◽  
Normal Blood Pressure ◽  
Change In Mean ◽  
Acupoint Stimulation

Abstract Background: High-normal blood pressure (BP) is associated with increased all-cause, cardiovascular mortality and frequently progresses to hypertension. Transcutaneous electrical acupoint stimulation (TEAS) might be a non-pharmaceutical therapy option to control BP. This trial aims to determine the efficacy and safety of TEAS combined with lifestyle modification for high-normal BP. Methods/design: This prospective, randomized and parallel clinical trial will be conducted in a community service center in China. Sixty participants with high-normal BP will be randomly allocated to receive TEAS plus lifestyle modification (intervention group) or lifestyle modification alone (control group) in a 1:1 ratio. In addition to lifestyle modification, the intervention group will receive TEAS at four acupoints for 30 minutes, 4 times weekly for 12 weeks for a total of 48 sessions at home. The control group will receive same lifestyle modification but no TEAS. The primary outcome will be the change in mean systolic blood pressure at 12-week from the baseline measurement. Secondary outcomes include the change of mean diastolic blood pressure, proportion of subjects with progression to hypertension, quality of life, physical activity, body mass index and waist circumference. Adverse events during the trial will be monitored. Discussion: This trial will explore the feasibility and provide potential evidence for the efficacy and safety of TEAS plus lifestyle modification for high-normal BP. The results of this study will be published in a peer-reviewed journal. Trial registration: Chinese Clinical Trial Registry, ChiCTR1900024982. Registered on August 6, 2019.

scholarly journals Transcutaneous electrical acupoint stimulation for high-normal blood pressure: study protocol for a randomized controlled pilot trial

2020 ◽  
Author(s):  
Yu Wang ◽  
Guang-Xia Shi ◽  
Zhong-Xue Tian ◽  
Jun-Hong Liu ◽  
You-Sheng Qi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Lifestyle Modification ◽  
Pilot Trial ◽  
Intervention Group ◽  
Normal Blood ◽  
Control Group ◽  
Normal Blood Pressure ◽  
Randomized Controlled ◽  
Acupoint Stimulation

Abstract Background:High-normal blood pressure (BP) is associated with increased all-cause, cardiovascular mortality and frequently progresses to hypertension. Transcutaneous electrical acupoint stimulation (TEAS) might be a non-pharmaceutical therapy option to control BP. This trial aims to determine the efficacy effectiveness and safety of TEAS combined with lifestyle modification for high-normal BP. Methods/design:This prospective, randomized and parallel clinical trial will be conducted in a community service center in China. Sixty participants with high-normal BP will be randomly allocated to receive TEAS plus lifestyle modification (intervention group) or lifestyle modification alone (control group) in a 1:1 ratio. In addition to lifestyle modification, the intervention group will receive TEAS at four acupoints for 30 minutes, 4 times weekly for 12 weeks for a total of 48 sessions at home. The control group will receive same lifestyle modification but no TEAS. The primary outcome will be the change in mean systolic blood pressure at 12-week from the baseline measurement. Secondary outcomes include the change of mean diastolic blood pressure, proportion of subjects with progression to hypertension, quality of life, physical activity, body mass index and waist circumference. Adverse events during the trial will be monitored.Discussion:This trial will explore the feasibility and provide potential evidence for the efficacy effectiveness and safety of TEAS plus lifestyle modification for high-normal BP. Furthermore, this pilot trial is being undertaken to determine the feasibility of a full scale definitive randomized controlled trial. The results of this study will be published in a peer-reviewed journal.Trial registration:Chinese Clinical Trial Registry, ChiCTR 1900024982. Registered on August 6, 2019.

THE BRACHIAL TO DIGITAL BLOOD PRESSURE GRADIENT IN NORMAL SUBJECTS AND IN PATIENTS WITH HIGH BLOOD PRESSURE

1958 ◽  
Vol 36 (9) ◽  
pp. 889-893 ◽  
Author(s):  
P. Gaskell ◽  
A. M. Krisman
Keyword(s):  
Blood Pressure ◽  
Pressure Gradient ◽  
Diastolic Pressure ◽  
Systolic Pressure ◽  
Normal Subjects ◽  
Normal Blood ◽  
Control Group ◽  
Normal Blood Pressure ◽  
Hypertensive Patients ◽  
Systolic Pressure Gradient

The brachial and digital blood pressures were estimated by auscultatory techniques in 10 patients with essential hypertension and in a group of 6 subjects with normal blood pressure who were in a state of regulated peripheral vasoconstriction and again when they were in a state of regulated vasodilatation. The brachial to digital systolic and diastolic pressure gradients in both control subjects and hypertensive patients were greater when the individuals were heated than when they were cooled. The brachial to digital diastolic pressure gradient in the hypertensive patients was not significantly different from that in the subjects with normal blood pressure. However, the systolic pressure gradient was greater in the hypertensive patients than in the control group both when the individuals were heated and when they were cooled.

Abstract P143: Cardiovascular Health Among Asian Americans, NHANES 2011-2014

Circulation ◽  
2018 ◽  
Vol 137 (suppl_1) ◽  
Author(s):  
Jing Fang ◽  
Zefeng Zhang ◽  
Carma Ayala ◽  
Angela Thompson-Paul ◽  
Fleetwood Loustalot
Keyword(s):  
Physical Activity ◽  
Blood Pressure ◽  
Cardiovascular Health ◽  
Normal Weight ◽  
Blood Cholesterol ◽  
Sensitivity Analyses ◽  
Normal Blood ◽  
Normal Blood Pressure ◽  
The Us ◽  
The U.S

Background: Non-Hispanic Asian Americans (AA) are one of the fastest growing populations in the U.S., yet little information is known about the cardiovascular health (CVH) of this group. The objective of this study was to assess the CVH of AA using a nationally representative survey. Methods: Merging data from the National Health and Nutrition Examination Surveys (NHANES) in 2011-2012 and 2013-2014, we examined 7 metrics of CVH using national guidelines and recommendations: not smoking, normal weight (body mass index, BMI <25 kg/m 2 ) , adequate physical activity, healthy diet, normal blood cholesterol , normal blood glucose and normal blood pressure. Each CVH metric was weighted evenly, with scores for each metric being a 0 (not meeting standards) or 1 (meeting current standards), and the metrics were summed for a total score. Ideal CVH (ICVH) was defined as the percentage of those meeting recommendations for 6-7 metrics, and poor CVH (PCVH) defined as those meeting only 0-2. We compared the prevalence of ICVH and PCVH between non-Hispanic whites (NHW) and AA, as well as among AA by birthplace and years living in the U.S. We also assessed the adjusted prevalence ratios (APR, 95% Confidence Intervals [CI]) of ICVH for AA, using NHW as referent, controlling for age, sex, education, and health insurance status. Additional sensitivity analyses were performed using a previously established Asian-specific normal weight cut-point (BMI<23 kg/m 2 ) for AA. Results: In adjusted models, AA were more likely to not smoke, have a normal weight, report a healthy diet and have normal blood pressure, compared with NHWs. However, NHWs were more likely to have normal blood glucose compared with AA, and no difference was identified with reported physical activity and blood cholesterol. The adjusted prevalence of ICVH was 9.2% for AA and 5.7% for NHWs (p<0.01). The adjusted percentage for PCVH was 26.6% for AA and 33.5% for NHWs (p<0.01). AA were significantly more likely to have ICVH (APR 1.41, 95% CI: 1.25-1.60) compared to NHW, but there was no difference in ICVH comparing US-born and foreign-born, nor by years living in the US. Additional sensitivity analyses using lower BMI thresholds for AA, consistently found a higher percentage of normal weight AA compared with NHW (36.4% vs 30.4, p<0.01); with no differences in the adjusted prevalence of ICVH (6.7% vs 5.7%, p=0.4) and PCVH (30.8% vs 33.5%, p=0.2) between AA and NHW (APR 1.18, 95% CI: 0.84-1.66). Conclusion: AA currently account for 5.3% of adult population in the US, and have been identified as one of the fasting growing minority populations. In this study, AA had a higher prevalence of overall ICVH compared with NHWs; however, when using a lower BMI threshold for AA as recommended by some, there was no difference of ICVH between AA and NHW. Using unique risk scores for AA may better identify AA with less than ideal cardiovascular health.

scholarly journals Transcutaneous electrical acupoint stimulation for high-normal blood pressure: study protocol for a randomized controlled pilot trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Yu Wang ◽  
Guang-Xia Shi ◽  
Zhong-Xue Tian ◽  
Jun-Hong Liu ◽  
You-Sheng Qi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Lifestyle Modification ◽  
Pilot Trial ◽  
Intervention Group ◽  
Normal Blood ◽  
Control Group ◽  
Normal Blood Pressure ◽  
Randomized Controlled ◽  
Acupoint Stimulation

Abstract Background High-normal blood pressure (BP) is associated with increased all-cause, cardiovascular mortality and frequently progresses to hypertension. Transcutaneous electrical acupoint stimulation (TEAS) might be a non-pharmaceutical therapy option to control BP. This trial aims to determine the effectiveness and safety of TEAS combined with lifestyle modification for high-normal BP. Methods/design This prospective, randomized, and parallel clinical trial will be conducted in a community service center in China. Sixty participants with high-normal BP will be randomly allocated to receive TEAS plus lifestyle modification (intervention group) or lifestyle modification alone (control group) in a 1:1 ratio. In addition to lifestyle modification, the intervention group will receive TEAS at four acupoints for 30 min, 4 times weekly for 12 weeks for a total of 48 sessions at home. The control group will receive same lifestyle modification but no TEAS. The primary outcome will be the change in mean systolic blood pressure at 12 weeks from the baseline measurement. Secondary outcomes include the change of mean diastolic blood pressure, proportion of subjects with progression to hypertension, quality of life, body mass index, and waist circumference. Adverse events during the trial will be monitored. Discussion This trial will explore the feasibility and provide potential evidence for the effectiveness and safety of TEAS plus lifestyle modification for high-normal BP. Furthermore, this pilot trial is being undertaken to determine the feasibility of a full scale definitive randomized controlled trial. The results of this study will be published in a peer-reviewed journal. Trial registration Chinese Clinical Trial Registry, ChiCTR 1900024982. Registered on August 6, 2019.

scholarly journals Comparison of Intraocular Pressure among Individuals with Systemic Hypertension and those with Normal Blood Pressure

2021 ◽  
Vol 13 (2) ◽  
pp. 137-144
Author(s):  
Sanket Parajuli ◽  
Pooja Shrestha ◽  
Jeevan K Shrestha ◽  
Sadhana Sharma
Keyword(s):  
Blood Pressure ◽  
Intraocular Pressure ◽  
Normal Blood ◽  
Systemic Hypertension ◽  
Control Group ◽  
Case Group ◽  
Normal Blood Pressure ◽  
Hypertensive Group ◽  
Significant Difference ◽  
The Right

Introduction: Systemic blood pressure, by far, is one of the most important factors that can have an effect on intraocular pressure. We have compared the intraocular pressure (IOP) among patients with systemic hypertension and those with normal blood pressure. Materials and methods: A hospital based case control study was conducted from March 2017 to March 2018 in the Ophthalmology outpatient department at Dhulikhel Hospital. A total of 100 patients with hypertension were included in the case group (hypertensive group) and 100 cases with no systemic or ocular disease were included in the control group (normotensive group). Mean intraocular pressures were calculated and compared between the two groups. Results: Mean age of patients was 49.03 years in hypertensive group and 47.53 years in normotensive group. Mean IOP of the right eye in those with hypertension was 16.10 mmHg and in the left eye was 15.8 mmHg. Similarly mean IOP of the right eye in the normotensive group was 15.8 mmHg and the left eye was 16.2 mmHg. The difference between mean IOP of hypertensive and normotensive individuals was not statistically significant (p > 0.05). The prevalence of ocular hypertension was found to be 7.5%. Conclusion: There was no statistically significant difference in IOP between hypertensive and normotensive individuals. However, a statistically significant difference in IOP was noted between ‘hypertensive with controlled blood pressure’ and ‘hypertensive with uncontrolled BP’ indicating that high blood pressure may be associated with high IOP.

scholarly journals Transcutaneous electrical acupoint stimulation for high-normal blood pressure: study protocol for a randomized controlled pilot trial

2020 ◽  
Author(s):  
Yu Wang ◽  
Guang-Xia Shi ◽  
Zhong-Xue Tian ◽  
Jun-Hong Liu ◽  
You-Sheng Qi ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Trial ◽  
Lifestyle Modification ◽  
Pilot Trial ◽  
Intervention Group ◽  
Normal Blood ◽  
Control Group ◽  
Normal Blood Pressure ◽  
Randomized Controlled ◽  
Acupoint Stimulation

Abstract Background: High-normal blood pressure (BP) is associated with increased all-cause, cardiovascular mortality and frequently progresses to hypertension. Transcutaneous electrical acupoint stimulation (TEAS) might be a non-pharmaceutical therapy option to control BP. This trial aims to determine the effectiveness and safety of TEAS combined with lifestyle modification for high-normal BP. Methods/design: This prospective, randomized and parallel clinical trial will be conducted in a community service center in China. Sixty participants with high-normal BP will be randomly allocated to receive TEAS plus lifestyle modification (intervention group) or lifestyle modification alone (control group) in a 1:1 ratio. In addition to lifestyle modification, the intervention group will receive TEAS at four acupoints for 30 minutes, 4 times weekly for 12 weeks for a total of 48 sessions at home. The control group will receive same lifestyle modification but no TEAS. The primary outcome will be the change in mean systolic blood pressure at 12-week from the baseline measurement. Secondary outcomes include the change of mean diastolic blood pressure, proportion of subjects with progression to hypertension, quality of life, physical activity, body mass index and waist circumference. Adverse events during the trial will be monitored.Discussion: This trial will explore the feasibility and provide potential evidence for the effectiveness and safety of TEAS plus lifestyle modification for high-normal BP. Furthermore, this pilot trial is being undertaken to determine the feasibility of a full scale definitive randomized controlled trial. The results of this study will be published in a peer-reviewed journal.Trial registration: Chinese Clinical Trial Registry, ChiCTR 1900024982. Registered on August 6, 2019.

Sign in / Sign up

Export Citation Format

Share Document